Table 3.

Odds ratios (confidence intervals) of clinical predictor variables for acute breast toxicity reported from multivariate regression in previously published studies with significant associations in bold (BMI, body mass index; fractionation, fractionation treatment schedule).

References	Twardella et al. (16)	Back (17)	Deantonio et al. (18)	Barnett et al. (19)	Terrazzino et al. (21)	Sharp et al. (22)	Tortorelli et al. (23)	Ciammella et al. (24)	De Langhe et al. (25)
N	478	234	155	1124	286	390	200	212	377
Proportion acute breast toxicity*	17.6%	31.4%	34.8%	36.5%	31.1%	21.3%	31.9%	15.0%	58.0%
Age (per year) Age ≥50	0.98 (0.96–1.01)	Not significant**				2.20 (1.00–4.80)	0.97 (0.94–1.01)	Not significant
BMI (per kg/m2) BMI ≥25 BMI ≥30	1.09 (1.05–1.13)	2.10 (1.00–4.60)			1.00 (0.92–1.09)	1.10 (0.60–2.10) 4.20 (2.10–8.30)			1.09 (not given)
Breast volume (per liter) Breast volume > median Breast size > median Breast diameter Breast cup size ≥D		3.60 (1.60–8.10)		2.09 (1.60–2.72)	1.14 (1.00–1.29)		1.00 (1.00–1.01)	2.47 (1.98–6.22)	2.83 (not given)
Fractionation Hypo- vs. conventional			0.45 (0.23–0.93)						0.08 (not given)
Conventional vs. hypo-						1.90 (1.00–3.50)	2.05 (1.00–4.20)
Boost use		Not significant			4.90 (1.46–16.48)			0.99 (0.98–1.00)
Hypertension								Not significant
Diabetes					Not significant			Not significant
Smoking	0.86 (0.44–1.70)				Not significant	2.50 (1.10–5.70)			2.71 (not given)
Postop infection		Not significant		1.49 (1.08–2.06)				3.46 (1.49–8.02)
Chemotherapy		Not significant	Not significant	0.58 (0.41–0.82)	Not significant	1.80 (1.01–3.33)	1.14 (0.53–2.43)	Not significant	0.95 (not given)
Tamoxifen use	1.54 (0.73–3.09)			1.23 (1.07–1.41)	Not significant	1.20 (0.70–2.10)	1.23 (0.55–2.77)

^*The proportion of patients with acute breast toxicity is shown according to each study's endpoint definition.

^**These studies only published p-values but no odds ratios for non-significant associations.